GLS has developed a very effective method of conducting clinical development in four to five nations and motivating the approvals in 45 to 50 commonwealth and 25 EU nations.

The Commonwealth Global Strategy (CGS) is just that — global. But on a strict budget. It is about conducting multinational clinical trials in full accordance with GCP, and leveraging the outcomes in 40+ nations. It is about establishing a global market opportunity on a strict budget.

Why GLS•CGS?

• 53 independent countries in the Commonwealth
• 2.0 billion people in the Commonwealth
• 30% of the world population
• 32 of these member countries are small states of less than 1.5 million people